ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Revance Therapeutics Inc

Revance Therapeutics Inc (RVNC)

3.78
-0.01
(-0.26%)
Closed April 21 4:00PM
3.78
0.00
(0.00%)
After Hours: 7:26PM

Get an advanced news scanner tailored to your needs by ADVFN

Enhance your trading experience

RVNC News

Official News Only

RVNC Discussion

View Posts
IanFromSI IanFromSI 50 minutes ago
Milton Friedman (Nobel prize winner for economics) famously said: “Inflation is always and everywhere a monetary phenomenon, in the sense that it is and can be produced only by a more rapid increase in the quantity of money than in output.”

For more than a decade, the fed gave money away for free or close to it and flooded the market with decade of quantitative easing or excess liquidity. . Those days are now over.

The fed is aggressively tightening and will continue to do so until inflation is definitely under control. This is definitely not the utopia emerging biotechs have become accustomed to.

Roy’s Blindspot appears to be managerial competence. MNTA lost its IP for two potential blockbusters in a row before investors were rescued by JNJ. I never followed.Enanta, I don’t know whether that was a managerial mistake or simply having a pipeline which became obsolete prior to enough approvals. … or something else.

The RVNC perma bulls Seem to be utterly disgusted with Foley. Not a good indicator for any company.

If the company is not profitable in a year, it may never be able to get there. …. And Roy’s track record in picking fabulous management is far from stellar.

Is it can take more than 10% of the toxin market within a year, it will probably survive.
👍️ 1
PioneerUniverse8 PioneerUniverse8 7 hours ago
Ian you seem like a smart guy, but you are too pessimistic about RVNC's prospects. With the pricing adjustment they have a fair shot at making a lot of money. I will reply to this post in about a year and admit that I was wrong, or that you were just unreasonably pessimistic.
👍️ 2
IanFromSI IanFromSI 1 day ago
Two more milestones are approaching, once reached, even more institutional investors will no longer be allowed to own RVNC.
💩 2 🤡 1 🤥 1
go seek go seek 1 day ago
High % Shorts… probably related to the weak market and options trading. I think the short trade will soon reverse on this one. Bottom probably was put in at $3.7., but I’m no expert. Hopefully we get some positive feedback from management in the near future.
👍️0
Emannow Emannow 1 day ago
Yesterday, the shorts were 61% of the trades and Thursday, 51%, Wednesday 60%…

Any thoughts on why the shorts would be working so hard to depress the SP?
👍️0
go seek go seek 2 days ago
💋 Are u ready for your close-up?
https://www.instagram.com/reel/C59Scu-JBSJ/?igsh=aDN1NW0zbWJhNGR1
👍️0
go seek go seek 2 days ago
$249… no crows feet!
https://www.instagram.com/reel/C5qpTlaAKQn/?igsh=OW9saXNhdmRiMDNl
👍️ 1
DewDiligence DewDiligence 3 days ago
Nothing has changed regarding double-dose Jeuveau since the post I'm replying to; it remains a gimmick that has little consequence in the marketplace.

Reply to 'iwfal' on Biotech Values board:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174265867
👍️ 6
go seek go seek 3 days ago
(Audio) How many customers stay w Daxxi?

https://www.instagram.com/reel/C2i6DfSO1Kd/?igsh=MWUzOXhxejgxb3hvaA==

Revive Clinic
👍️ 2
edcoolidge edcoolidge 3 days ago
Clearly the EOLS data was meant to convince unsophisticated CosmetcMDs and not investors.
👍️ 1 🤡 1
go seek go seek 3 days ago
Yesterday I asked Candice Roberts, NP of Robert’s Aesthetics and Wellness in Houma, Louisiana… Do people who try Daxxi, stay w Daxxi? She emphatically stated ‘Yes’[ and they ask ’Why haven’t I seen this product sooner!’

My question is at 29:30 on following video…

https://app.livestorm.co/p/a2ca04e7-9725-486c-8fe8-3c64e6e21c67/live?email=bh10ok%40gmail.com&key=96c83a9e50f479c614c12c&s=a909b1e7-3275-4ea9-9a1c-0e1eb6c80265
👍️ 6 💯 2
imnot6 imnot6 3 days ago
Added @3.72. Hope to look back at this as a decent calculated risk.
👍️ 3
stocksrising stocksrising 3 days ago
‘Proud’ naked seller that if exercised will have a 2 handle, and almost a 1 after taking in $.40( SMH)

Sell to Open 50 Contracts
RVNC Oct 18 2024 2.5 Puts Limit at $0.40 (Good 'til
Canceled)
-RVNC241018P2.5 PUT (RVNC) REVANCE
THERAPEUTICSOCT 18 24
$2.5 (100 SHS)

Filled at $0.40 Apr-16-2024
👍️0
biotech_researcher biotech_researcher 3 days ago
Where is the brokerage coverage to defend the stock? They are going to need cash at some point..
👍️ 1
iwfal iwfal 3 days ago
My guess is the entire double dose strategy was not to make money on a longer duration formulation per se, but rather for competitive reasons to upend any perception that daxi was special or unique

Agree completely this is true. For now. But is likely to change once Daxxy starts cutting into their growth/sales.
👍️ 1
dewophile dewophile 3 days ago
I agree they won't run a registrational trial, and I doubt they sink any meaningful money into this program for now
My guess is the entire double dose strategy was not to make money on a longer duration formulation per se, but rather for competitive reasons to upend any perception that daxi was special or unique
👍️ 3
boraborak38 boraborak38 4 days ago
No need for Phase 3. They are aesthetic only. No need for that cost. And I don’t think they do a frontalis study.
👍️ 3
go seek go seek 4 days ago
So in 2 weeks (1 May) we have the Annual Meeting, and the 1st quarter earnings call will follow about a week later. It’s about time this stock…
👍️0
iwfal iwfal 4 days ago
Hmm… would they need P3 study and BLA for this?

No particular reason they need to get a new label. I doubt they’d even try.

A more interesting question is when/if they try to formalize a scheme to get similar duration with frontalis.
👍️ 1
edcoolidge edcoolidge 4 days ago
One point improvement lol. I'm sure some unscrupulous CosmeticMDs will be happy to run with this deceit.
👍️ 2 🤡 1
Tomdontworry Tomdontworry 4 days ago
Hmm… would they need P3 study and BLA for this? Are we talking minimum 2 years before these hit the market?
👍️ 1
iwfal iwfal 4 days ago
EOLS Extra Strength As for Dew’s assertion that they will never publish… I’d wager they do publish (paper or poster), but there is no urgency to do so until they feel Daxxy is starting to impact their growth.

They did, in fact, publish. And earlier than I would have expected.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174257910
👍️ 2
Paob Paob 4 days ago
That raise caused significant dilution and since there was no change to their 2024 forecast, it meant it was to cover EXISTING expenses, not further growth. Their financial strategy this year and second half of last year has been about raising cash.
👍️0
vinmantoo vinmantoo 4 days ago
If the injectors avoid stocking Daxxi, that is not good.

What happens when injectors use Daxxify more frequently and stock up? Is that good?
👍️ 2
edcoolidge edcoolidge 4 days ago
Bulls certainly underestimated how many pathetic and unscrupulous CosmeticMDs exist in aesthetics but many injectors are stocking Daxxify and I see new practices announcing it daily.
👍️ 3 🤡 2
biotech_researcher biotech_researcher 4 days ago
The ugliest thing is the competition and their proxies are rallying around stopping RVNC’s progress. If the injectors avoid stocking Daxxi, that is not good.
👍️ 2
usma67korea usma67korea 5 days ago
Q1 is never a good qtr for most bioland stocks. don't expect that to be diff here. and ceo has said so in prior comments. i think key is keeping the same 2024 overall guidance even w/ soft q1 #s (which i expect). and maybe, just maybe in Q2 or Q3 ER, they can actually beat the guidance and/or raise 2024 overall #s. that would be something. i don't think Q1 # by itself means much as long as overall 2024 # is in tact or even higher than $280 guidance.. (of course if lower guidance, then sure, we will lose even the $3 handle maybe), but i am here for 4-6 qtrs as this will take a lot of time to play out
👍️ 5 💯 1
Lishur Lishur 5 days ago
Added 3.83
👍️ 1
PioneerUniverse8 PioneerUniverse8 5 days ago
if q1 numbers don't fit into that $280 million EOY revenue picture, it will get much uglier. We will know soon enough.
👍️ 3 💩 2
usma67korea usma67korea 5 days ago
w/ RVNC, not a stock you want to be watching tick by tick every day. that will make LT holders suicidal. i have been in RVNC for years (did exit a couple of times too), and recently entered, and I knew this would be a very long turnaround, if at all. i think we get Q1 ER out of the way (nothing special prob.) and need to see Q2 and Q3 to be the pivot point to turn this around. usually before that happens, share price would have bottomed well beforehand. i think 3.7 today would turn out to be the bottom.
👍️ 2
vinmantoo vinmantoo 5 days ago
Bought more.

I sold a bit today at $3.87 to generate a tax loss I need for 2024 tax year. I still own close to my highest share level ever. I kept waiting for RVNC price to stabilize but it doesn't look like it right now. I plan to buy the shares back when the wash period has ended, and the way RVNC is going, I doubt it will be at a much higher price if higher at all. Good luck on your most recent buy. I added a bit more ABBV. With geopolitical tensions rising. I went for a solid stock with lots of cash.
👍️ 1
vinmantoo vinmantoo 5 days ago
3.8....unreal.

One thing I learned from investing is that just when I think a stock price can't get any lower. it goes lower.
👍️0
stocksrising stocksrising 5 days ago
Will also be buying $3ish print today as well as currently offering out 50 puts @ $2.5 strike(Oct 18th expire) …
👍️0
Tomdontworry Tomdontworry 5 days ago
I thought the same, for 40M big fish can take 10% of MC and clean house.
Another issue i see is SG&A for Revence - similar revenue to Evolus but $130M more expenses.
👍️ 1
iwfal iwfal 5 days ago
Therapeutics might be the only way out of this mess.

No:

A) ~half the therapeutic market is migraine, on which Allergan has patents.
B) it’s going to take significant time to develop the Daxxy specific protocol on Spastic Limb, which is the majority of the remainder
C) by having to lower their price in aesthetics, and, unlike Allergan, using the same price in therapeutics plus lasting longer per treatment, the total market will be much lower.

There isn’t that much near term (next few years) money for Revance in therapeutics.
👍️ 2
DaveAu DaveAu 5 days ago
This company would be a good target for an activist investor to get involved in. I'm pretty sure investors wouldn't support the current board.
👍️ 4
randychub randychub 5 days ago
Bought more.
👍️0
PioneerUniverse8 PioneerUniverse8 5 days ago
all of a sudden now that $6.25 raise looks phenomenal
👍️ 2
alertmeipp alertmeipp 5 days ago
3.8....unreal.
👍️ 1
biotech_researcher biotech_researcher 5 days ago
Therapeutics might be the only way out of this mess.
👍️ 1
mrwilson31 mrwilson31 6 days ago
Wow!!!
👍️0
vinmantoo vinmantoo 6 days ago
Well, closed under $4/share. Some day RVNC will stop going down. I just hope it is before it gets to zero. 🤣

A little gallows humor.
👍️ 2 😃 1 🥹 1
DewDiligence DewDiligence 6 days ago
Those are ancillary data on retreatment intervals from the ASPEN-1 and ASPEN–OLS trials. Worth knowing, but not market-moving.
👍️ 2
go seek go seek 6 days ago
I’m sure the data presented are positive for Daxxi and Revance, but this data won’t move the stock.
👍️0
girlfriend girlfriend 6 days ago
Is any body expecting positive data on Daxxify from the conference currently taking place: https://ih.advfn.com/stock-market/NASDAQ/revance-therapeutics-RVNC/stock-news/93643006/revance-to-present-new-daxxify-data-at-the-americ
🤡 1
stocksrising stocksrising 6 days ago
Yes sir, agreed..mainly it’s regarding 3rd Tranche, and if he can share any color( which is doubtful, but never know til you ask) or do we have to wait for Q1 CC…Will update if anything meaningful
👍️0
Emannow Emannow 6 days ago
Just an example, there is a Med Spa doctor in the Mid Atlantic and she makes $140,000 plus annually published on the Sunshine Act as a speaker for Botox/Juvederm. My guess is the practice also get $40,000 to $60,000 in free staff training products which are sold to patients at full price. This type of bribery goes on all across the USA with dozens of injectors.

This Med Spa doctor will not even see the RVNC rep!!!
👍️ 2 💯 1
stocksrising stocksrising 6 days ago
Pretty sure this is the same Laurence( his says New Street) that is the contact person, but just him VM and start repore

Investors
Laurence Watts, 619-916-7620
laurence@newstreetir.com
👍️0
edcoolidge edcoolidge 6 days ago
Some aesthetics practices may genuinely not be offering Daxxify because they were turned off by their interactions with their Revance sales rep or management but that doesn't really pass the smell test. It's clear many unscrupulous CosmeticMDs are being compensated financially by Abbvie/Galderma one way or another to steer their patients towards the legacy toxins and maintain the status quo. In therapeutics payers will have a very strong incentive to switch patients to the best toxin with the best price (Daxxify) and the doctors don't have a conflict of interest that violates their Hippocratic oath.
👍️ 1 🤡 1
DewDiligence DewDiligence 6 days ago
The new IR firm (#msg-174240308) should be able to answer any question that Jessica could.
👍️ 2

Your Recent History

Delayed Upgrade Clock